Physician profile
Christopher A Puckett
NPI 1831130806
$2,779.79
in general payments reported to CMS, 2019-2025
38 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.16 · 2020: $114 · 2021: $57.02 · 2022: $301 · 2023: $665 · 2024: $614 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.47 |
| Education | $362.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $449.39 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $248.21 | 2021-2025 | |
| Genzyme Corporation | $233.86 | 2022-2025 | |
| Shockwave Medical, INC | $141.41 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Biotech, INC. | $116.41 | 2022-2024 | Erleada, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $111.42 | 2022-2025 | Imfinzi, Enhertu |
| Sanofi-Aventis U.S. LLC | $98.00 | 2024 | |
| Daiichi Sankyo INC. | $97.19 | 2020-2025 | Injectafer, Datroway, Enhertu |
| Veran Medical Technologies, INC. | $83.99 | 2020 | |
| Merck Sharp & Dohme LLC | $82.19 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Array Biopharma INC | $81.08 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Celgene Corporation | $75.54 | 2023-2025 | Reblozyl, Opdualag, Pomalyst |
| Emd Serono, INC. | $69.71 | 2022-2025 | Bavencio |
| Sobi, INC | $69.09 | 2022-2023 | |
| Abbvie INC. | $67.83 | 2024-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $67.49 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Abbott Laboratories | $67.19 | 2024-2025 | Proclaim |
| Amgen INC. | $58.62 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Rigel Pharmaceuticals, INC. | $57.95 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| E.R. Squibb & Sons, L.L.C. | $52.29 | 2023-2024 | Opdivo |
| Incyte Corporation | $50.12 | 2025 | Monjuvi, Zynyz, Jakafi |
| Gilead Sciences, INC. | $38.17 | 2025 | Trodelvy |
| Astellas Pharma US INC | $35.54 | 2021-2022 | |
| Genentech USA, INC. | $31.15 | 2024-2025 | Tecentriq Hybreza, Tecentriq, Phesgo |
| Myriad Genetic Laboratories, INC. | $30.91 | 2023-2025 | Myrisk |
| Immunocore Limited | $30.04 | 2025 | Kimmtrak |
| Aveo Pharmaceuticals, INC. | $26.87 | 2023 | Fotivda |
| Tersera Therapeutics LLC | $25.37 | 2023 | Zoladex |
| Seagen INC. | $21.45 | 2022 | |
| Pharmacosmos Therapeutics INC. | $21.40 | 2023 | Monoferric |
| Verity Pharmaceuticals INC. | $21.01 | 2023 | Trelstar |
| Tempus Ai, INC | $20.17 | 2025 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.32 | 2025 | |
| Accord Healthcare, INC. | $17.59 | 2023 | |
| Agios Pharmaceuticals, INC. | $17.40 | 2025 | Pyrukynd |
| Blue Earth Diagnostics | $15.94 | 2023 | |
| Pharmaessentia USA Corporation | $14.40 | 2025 | Besremi |
| Secura Bio, INC. | $14.08 | 2025 | Copiktra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Puckett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.